A head-to-head trial comparing the decades-old steroid, prednisone, and a promising new steroid, vamorolone, finds both act on the same key set of genetic pathways involved in controlling inflammation, indicates a new study. However, the study suggests the new investigational steroid doesn't activate several additional pathways involved in prednisone's bevy of undesirable side effects.